Better Care Seeks €1.5 Million to Expand Internationally

Better Care is looking for more capital to grow. The Catalan biotech company specializing in technology for continuous patient monitoring using artificial intelligence (AI) has opened a new round of financing with the aim of raising €1.5 million to make the leap internationally, according to Xavier García, director General of Better Care.

The company is studying the possibility of the Capital Cell crowdfunding platform participating in the financing round with the aim of giving access and opportunity to small investors with smaller tickets. According to García, the company from Sabadell (Barcelona) is currently valued at more than €10 million.

The resources obtained by Better Care in this capital increase will be used to incorporate talent for its growth and international expansion. Likewise, the company will improve procedures in the area of ​​software development, will consolidate new opportunities in healthcare areas in different autonomous communities, and will expand into the US and Canadian markets in a few months.

If you want to find more details about Better Care and read the most important financial news of the day, download for free our companion app. The Born2Invest mobile app is available for free, for both Android and iOS devices.

Better Care has obtained to date €800,000 of private financing and half a million euros of public aid 

In the last year, the company has raised €800,000 in a financing round in which family offices and private investors have participated. €500,000 of European funding is added to this capital.

García explained that the use of data in health accelerates diagnoses and can help prevent diseases with the implementation of new indicators. For the general director of Better Care, the problem lies in the interoperability of the data and, therefore, he comments that “we develop solutions, hand in hand with the health professionals themselves, that offer all the biomedical data generated by the patient centrally and facilitating decision making.

Better Care is a company founded in 2010 at the Parc Taulí l I3PT Research and Innovation Institute in Sabadell, which was conceived as an innovation project within the hospital itself to respond to its real needs.

The company’s first solution was to develop software that would manage and integrate data and information from different medical devices and manufacturers. The company optimizes the data load of a patient to make decisions about her health, as well as to investigate a pathology.

The company works with more than thirty hospital centers

Better Care has spent more than a decade collaborating and researching with managers and different health specialties that intervene in the centers. Better Care software is currently available in more than thirty hospitals in twelve countries.

In 2022, the company reached a turnover of €1 million, compared to half a million euros it achieved in 2021. By 2023, the Catalan biotech company plans to exceed €4 million in revenue.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.